started · updated
Pimicotinib shows sustained benefits in TGCT phase 3 trial
Two-year data from the phase 3 MANEUVER trial indicate that pimicotinib (ABSK021) provides durable responses and sustained improvements for patients with tenosynovial giant cell tumor (TGCT).
According to findings presented at the ESMO Congress 2026, the objective response rate (ORR) remained stable, with the tumor volume score (TVS) increasing from 74.6% at one year to 77.8% at two years. Clinical improvements, including a 19.6% increase in mean joint mobility by week 97, were observed alongside reductions in pain and stiffness.
The global, randomized, double-blind, placebo-controlled study involved 40 sites across China, North America, and Europe. Investigators concluded that the treatment offers long-term antitumor activity and a predictable safety profile for adults with symptomatic, unresectable, and measurable TGCT.
Entities
ESMO Congress · Hans Gelderblom · Leiden University Medical Center · MANEUVER trial · Pimicotinib